

Per Morten Sandset

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/266259/publications.pdf>

Version: 2024-02-01

323
papers

12,710
citations

28274

55
h-index

32842

100
g-index

328
all docs

328
docs citations

328
times ranked

10078
citing authors

#	ARTICLE	IF	CITATIONS
1	Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonistsâ€”The PROPER3 Randomized Clinical Trial. <i>Annals of Emergency Medicine</i> , 2022, 79, 20-30.	0.6	9
2	Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 126-132.	3.8	6
3	Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1288-1295.	3.4	3
4	External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1379-1383.	3.4	4
5	Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients â€” 30 months followâ€”up. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1166-1181.	3.8	23
6	Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER). <i>Thrombosis Research</i> , 2022, 213, 119-124.	1.7	4
7	Two <i>SERPINC1</i> variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. <i>Blood</i> , 2022, 140, 140-151.	1.4	11
8	Editor's Choice â€” European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , 2021, 61, 9-82.	1.5	308
9	Utility of coagulation analyses to assess thromboprophylaxis with dalteparin in intensive care unit patients. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 489-498.	1.6	3
10	Predictors of long-term post-thrombotic syndrome following high proximal deep vein thrombosis: a cross-sectional study. <i>Thrombosis Journal</i> , 2021, 19, 3.	2.1	12
11	Effects of a 1-Year Physical Activity Intervention on Markers of Hemostasis among Breast Cancer Survivors: A Randomized Controlled Trial. <i>TH Open</i> , 2021, 05, e14-e23.	1.4	2
12	Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 5127.	3.3	11
13	Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1729-1737.	3.8	5
14	Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?. <i>Blood Advances</i> , 2021, 5, 2516-2517.	5.2	1
15	The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 5762.	2.5	0
16	Prior Thromboembolic Disease and Assisted Reproductive Therapy. <i>Seminars in Reproductive Medicine</i> , 2021, 39, 180-185.	1.1	0
17	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1874-1882.	3.8	122
18	Postâ€”thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A longâ€”term crossâ€”sectional followâ€”up of REâ€”COVER study patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2495-2503.	3.8	12

#	ARTICLE	IF	CITATIONS
19	ARTS: A Large, International Trial of Thromboprophylaxis in Intra-abdominal, Gynecologic, and Urologic Surgery. <i>European Urology Focus</i> , 2021, 7, 1222-1225.	3.1	3
20	Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up. <i>Blood</i> , 2021, 138, 3231-3231.	1.4	0
21	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. <i>Platelets</i> , 2020, 31, 43-47.	2.3	3
22	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. <i>Platelets</i> , 2020, 31, 198-205.	2.3	19
23	Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. <i>Platelets</i> , 2020, 31, 322-328.	2.3	6
24	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. <i>Thrombosis Research</i> , 2020, 185, 119-124.	1.7	20
25	Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification. <i>European Stroke Journal</i> , 2020, 5, 174-183.	5.5	6
26	Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. <i>OncImmunology</i> , 2020, 9, 1824644.	4.6	17
27	Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2958-2967.	3.8	98
28	Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. <i>Thrombosis Research</i> , 2020, 196, 238-244.	1.7	5
29	Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature. <i>International Journal of Cancer</i> , 2020, 147, 3189-3198.	5.1	11
30	Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells. <i>Scientific Reports</i> , 2020, 10, 4036.	3.3	7
31	Characterizing Coagulation FVII from iPSC-Hepatocytes-like Cells: Setting the Basis for Cell Therapy Development. <i>Blood</i> , 2020, 136, 4-4.	1.4	0
32	Successful Pregnancy in a Patient with Infertility Due to Congenital Plasminogen Deficiency Treated with Intravenous Plasminogen (Human) Replacement Therapy. <i>Blood</i> , 2020, 136, 5-6.	1.4	1
33	Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
34	Painting the Clinical Picture of Congenital Plasminogen Deficiency (C-PLGD) through a Comprehensive Case Study Review. <i>Blood</i> , 2020, 136, 21-22.	1.4	9
35	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1398-1399.	3.8	0
36	Does the Villalta scale capture the essence of postthrombotic syndrome? A qualitative study of patient experience and expert opinion. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1707-1714.	3.8	9

#	ARTICLE	IF	CITATIONS
37	Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1481-1488.	3.4	4
38	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials. <i>Stroke</i> , 2019, 50, 2187-2196.	2.0	13
39	Limitations of the Villalta scale in diagnosing post-thrombotic syndrome. <i>Thrombosis Research</i> , 2019, 184, 62-66.	1.7	9
40	Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women. <i>Thrombosis Research</i> , 2019, 184, 1-7.	1.7	21
41	The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII. <i>Cell and Bioscience</i> , 2019, 9, 69.	4.8	8
42	Is venous thromboembolism a problem in patients with cancer in palliative care?. <i>Lancet Haematology</i> , 2019, 6, e61-e62.	4.6	4
43	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 499-506.	3.8	6
44	The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis. <i>Thrombosis Research</i> , 2019, 177, 154-156.	1.7	1
45	Transcription factor FOXP3: A repressor of the <i>TFPI</i> gene?. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 12924-12936.	2.6	3
46	Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 17-23.	1.0	6
47	Venous thromboembolism in the critically ill: A prospective observational study of occurrence, risk factors and outcome. <i>Acta Anaesthesiologica Scandinavica</i> , 2019, 63, 630-638.	1.6	20
48	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. <i>Platelets</i> , 2019, 30, 206-212.	2.3	21
49	Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding (PROPER3). <i>BMJ Open</i> , 2018, 8, e020764.	1.9	12
50	Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency. <i>Thrombosis and Haemostasis</i> , 2018, 47, 664-675.	3.4	4
51	Factor VII deficiency: Unveiling the cellular and molecular mechanisms underlying three model alterations of the enzyme catalytic domain. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 660-667.	3.8	11
52	Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. <i>Blood</i> , 2018, 131, 1301-1310.	1.4	27
53	Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. <i>Thrombosis Research</i> , 2018, 163, 6-11.	1.7	33
54	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 128-131.	1.7	4

#	ARTICLE	IF	CITATIONS
55	Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis. <i>European Urology</i> , 2018, 73, 236-241.	1.9	67
56	Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis. <i>European Urology</i> , 2018, 73, 242-251.	1.9	85
57	Healthcare utilisation, induced labour and caesarean section in the pregnancy after stillbirth: a prospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 202-210.	2.3	10
58	Diagnostic scales for the post-thrombotic syndrome. <i>Thrombosis Research</i> , 2018, 164, 110-115.	1.7	27
59	Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2024-2034.	3.8	12
60	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). <i>Journal of Headache and Pain</i> , 2018, 19, 76.	6.0	64
61	Normalization of disrupted clock gene expression in males with tetraplegia: a crossover randomized placebo-controlled trial of melatonin supplementation. <i>Spinal Cord</i> , 2018, 56, 1076-1083.	1.9	9
62	Anxiety, depression and relationship satisfaction in the pregnancy following stillbirth and after the birth of a live-born baby: a prospective study. <i>BMC Pregnancy and Childbirth</i> , 2018, 18, 41.	2.4	41
63	Tissue Factor Pathway Inhibitor Enhances Transendothelial Migration of Chronic Lymphocytic Leukemia Cells through Binding to Glypican-3. <i>Blood</i> , 2018, 132, 2452-2452.	1.4	0
64	Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA). <i>Blood</i> , 2018, 132, 2511-2511.	1.4	0
65	The Chemical Chaperone 4-Phenylbutyrate Increases Secretion and Activity of Missense and Elongated Factor VII Mutants. <i>Blood</i> , 2018, 132, 3777-3777.	1.4	0
66	Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1. <i>Molecular and Cellular Endocrinology</i> , 2017, 443, 80-88.	3.2	6
67	Scoring Systems for Postthrombotic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 500-504.	2.7	18
68	Increased expression of TFPI in human carotid stenosis. <i>Thrombosis Research</i> , 2017, 155, 31-37.	1.7	4
69	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 49-56.	2.3	11
70	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. <i>Thrombosis Journal</i> , 2017, 15, 6.	2.1	32
71	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). <i>Journal of Headache and Pain</i> , 2017, 18, 108.	6.0	130
72	Tissue factor pathway inhibitor attenuates ER stress-induced inflammation in human M2-polarized macrophages. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 442-448.	2.1	19

#	ARTICLE	IF	CITATIONS
73	Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence. <i>Seminars in Neurology</i> , 2017, 37, 366-375.	1.4	0
74	Î²-Thromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2017, 77, 679-684.	1.2	4
75	Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. <i>PLoS ONE</i> , 2017, 12, e0176527.	2.5	10
76	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. <i>Thrombosis Research</i> , 2017, 157, 111-116.	1.7	21
77	Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4551-4551.	1.6	2
78	Pivotal Trial with Intravenous Plasminogen Replacement in Patients with Plasminogen Deficiency Demonstrates Long-Term Efficacy for Treatment and Prevention of Ligneous Lesions. <i>Blood</i> , 2017, 130, 84-84.	1.4	1
79	Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome. <i>Thrombosis and Haemostasis</i> , 2016, 115, 361-367.	3.4	39
80	Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 95-99.	2.7	12
81	The role of microRNAâ€27a/b and microRNAâ€494 in estrogenâ€mediated downregulation of tissue factor pathway inhibitor Î±. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1226-1237.	3.8	28
82	Health-related quality of life after pulmonary embolism: a cross-sectional study. <i>BMJ Open</i> , 2016, 6, e013086.	1.9	61
83	Health-related quality of life after deep vein thrombosis. <i>SpringerPlus</i> , 2016, 5, 1278.	1.2	36
84	MP46-06 SERIES OF SYSTEMATIC REVIEWS AND META-ANALYSES OF THE RISK OF THROMBOSIS AND BLEEDING IN UROLOGICAL NON-CANCER SURGERY (ROTBUS NON-CANCER). <i>Journal of Urology</i> , 2016, 195, .	0.4	0
85	PD25-03 SERIES OF SYSTEMATIC REVIEWS AND META-ANALYSES OF THE RISK OF THROMBOSIS AND BLEEDING IN UROLOGICAL CANCER SURGERY (ROTBUS CANCER). <i>Journal of Urology</i> , 2016, 195, .	0.4	0
86	Compression Stockings for Preventing the Postthrombotic Syndrome in Patients with Deep Vein Thrombosis. <i>American Journal of Medicine</i> , 2016, 129, 447.e1-447.e20.	1.5	23
87	Polymorphisms of the coagulation system and risk of cancer. <i>Thrombosis Research</i> , 2016, 140, S49-S54.	1.7	16
88	Determinants of acquired activated protein C resistance and D-dimer in breast cancer. <i>Thrombosis Research</i> , 2016, 145, 78-83.	1.7	8
89	Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 387-396.	3.8	18
90	Functional characterization of annexin A5 gene promoter allelic variants. <i>Thrombosis Research</i> , 2016, 144, 93-99.	1.7	7

#	ARTICLE	IF	CITATIONS
91	Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 418-424.	2.4	4
92	The role of inflammation in post-thrombotic syndrome after pregnancy-related deep vein thrombosis: A population-based, cross-sectional study. <i>Thrombosis Research</i> , 2016, 138, 16-21.	1.7	10
93	Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1308-1313.	3.8	364
94	Women's values and preferences and health state valuations for thromboprophylaxis during pregnancy: A cross-sectional interview study. <i>Thrombosis Research</i> , 2016, 140, 22-29.	1.7	23
95	EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 670-678.	3.8	27
96	Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. <i>Lancet Haematology</i> , 2016, 3, e64-e71.	4.6	311
97	Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5' Flanking Region. <i>PLoS ONE</i> , 2016, 11, e0152114.	2.5	6
98	Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. <i>Breast Cancer Research</i> , 2015, 17, 44.	5.0	24
99	The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells through the GRASP55 pathway. <i>Cell and Bioscience</i> , 2015, 5, 57.	4.8	9
100	Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 329-337.	2.1	65
101	Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. <i>Thrombosis and Haemostasis</i> , 2015, 114, 964-968.	3.4	7
102	Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP). <i>Thrombosis and Haemostasis</i> , 2015, 113, 870-880.	3.4	32
103	Women's Values and Preferences for Thromboprophylaxis during Pregnancy: A Comparison of Direct-choice and Decision Analysis using Patient Specific Utilities. <i>Thrombosis Research</i> , 2015, 136, 341-347.	1.7	23
104	Effects of Blood Pressure-Lowering Treatment in Different Subtypes of Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 877-879.	2.0	30
105	Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled cross-over study of melatonin. <i>Spinal Cord</i> , 2015, 53, 285-290.	1.9	10
106	Long-term outcome after pregnancy-related venous thrombosis. <i>Thrombosis Research</i> , 2015, 135, S1-S4.	1.7	11
107	Quality of life after pulmonary embolism: first cross-cultural evaluation of the pulmonary embolism quality-of-life (PEmb-QoL) questionnaire in a Norwegian cohort. <i>Quality of Life Research</i> , 2015, 24, 417-425.	3.1	21
108	Genetic variations in the annexin A5 gene and the risk of pregnancy-related venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 409-413.	3.8	10

#	ARTICLE	IF	CITATIONS
109	Adherence to mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2015, 136, 723-726.	1.7	19
110	Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. <i>Intensive Care Medicine</i> , 2015, 41, 1209-1219.	8.2	55
111	Theme 4: Invasive management of (recurrent) VTE and PTS. <i>Thrombosis Research</i> , 2015, 136, S19-S25.	1.7	6
112	Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2479-2481.	1.3	2
113	Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. <i>Thrombosis Research</i> , 2015, 135, 167-174.	1.7	17
114	Syndecan-3 and TFPI Colocalize on the Surface of Endothelial-, Smooth Muscle-, and Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0117404.	2.5	21
115	Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. <i>BMC Cancer</i> , 2014, 14, 845.	2.6	35
116	Combined oral contraceptives increase risk of venous thrombosis according to oestrogen dose and type of progestogen. <i>Evidence-Based Medicine</i> , 2014, 19, 194-194.	0.6	3
117	Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. <i>Systematic Reviews</i> , 2014, 3, 150.	5.3	49
118	Residual rates of reflux and obstruction and their correlation to post-thrombotic syndrome in a randomized study on catheter-directed thrombolysis for deep vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2014, 2, 123-130.	1.6	34
119	Oestrogen induced downregulation of TFPI expression is mediated by ER α . <i>Thrombosis Research</i> , 2014, 134, 138-143.	1.7	14
120	Adaptation of Trustworthy Guidelines Developed Using the GRADE Methodology. <i>Chest</i> , 2014, 146, 727-734.	0.8	18
121	TFPI 1 and TFPI 2 are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. <i>Journal of Hematology and Oncology</i> , 2013, 6, 5.	17.0	27
122	Long-term mortality and incidence of cancer after pregnancy-related venous thrombosis: Results of a population-based cohort study. <i>Thrombosis Research</i> , 2013, 131, 497-501.	1.7	9
123	Classification of stillbirths and risk factors by cause of death – a case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 325-333.	2.8	35
124	Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 177-184.	1.4	21
125	Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. <i>Thrombosis Research</i> , 2013, 131, 178-182.	1.7	19
126	Mechanisms of hormonal therapy related thrombosis. <i>Thrombosis Research</i> , 2013, 131, S4-S7.	1.7	33

#	ARTICLE	IF	CITATIONS
127	Determinants of Early and Long-term Efficacy of Catheter-directed Thrombolysis in Proximal Deep Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 17-24.	0.5	76
128	Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. <i>Lancet Neurology</i> , The, 2013, 12, 539-545.	10.2	110
129	Women's experiences in relation to stillbirth and risk factors for long-term post-traumatic stress symptoms: a retrospective study. <i>BMJ Open</i> , 2013, 3, e003323.	1.9	49
130	Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis. <i>Patient Related Outcome Measures</i> , 2013, 4, 55.	1.2	9
131	Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1032-1042.	3.8	45
132	Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. <i>BMJ Open</i> , 2013, 3, e002984.	1.9	76
133	Genotype of proband and thrombophilia screening. <i>Blood</i> , 2013, 122, 2528-2529.	1.4	1
134	The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. <i>Thrombosis and Haemostasis</i> , 2013, 109, 606-613.	3.4	22
135	Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study. <i>BMJ Open</i> , 2012, 2, e002048.	1.9	25
136	Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Ischemic Stroke due to Postmenopausal Hormone Therapy. <i>Stroke</i> , 2012, 43, 952-957.	2.0	16
137	Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. <i>Lancet</i> , The, 2012, 379, 31-38.	13.7	809
138	Catheter-directed thrombolysis for acute deep vein thrombosis - Authors' reply. <i>Lancet</i> , The, 2012, 379, 1786-1787.	13.7	1
139	Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , 2012, 158, 811-814.	2.5	24
140	Venous thromboembolism associated with pregnancy and hormonal therapy. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 319-332.	1.7	42
141	CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer. <i>Thrombosis Research</i> , 2012, 129, S97-S100.	1.7	15
142	C0385 Mortality after pregnancy-related venous thrombosis. <i>Thrombosis Research</i> , 2012, 130, S124.	1.7	0
143	C0298 Differential risk factors for pregnancy related deep vein thrombosis and pulmonary embolism' results from a population-based case-control study. <i>Thrombosis Research</i> , 2012, 130, S122-S123.	1.7	0
144	C0380 Long-term impact of venous thrombosis on quality of life, general health and functioning: A cross-sectional, case-control study. <i>Thrombosis Research</i> , 2012, 130, S123-S124.	1.7	0

#	ARTICLE	IF	CITATIONS
145	The association of antiphospholipid antibodies with intrauterine fetal death: A case-control study. <i>Thrombosis Research</i> , 2012, 130, 32-37.	1.7	22
146	Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - A European Perspective. <i>Thrombosis Research</i> , 2012, 129, 426-433.	1.7	68
147	A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. <i>Thrombosis Research</i> , 2012, 130, 45-51.	1.7	9
148	Long-term impact of intrauterine fetal death on quality of life and depression: a case-control study. <i>BMC Pregnancy and Childbirth</i> , 2012, 12, 43.	2.4	22
149	Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF- κ B and apoptosis mediated by a caspase-3 independent pathway. <i>Molecular Biology Reports</i> , 2012, 39, 10089-10096.	2.3	2
150	Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1165-1171.	3.4	14
151	Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 840-847.	3.8	80
152	Candidate gene polymorphisms and the risk for pregnancy-related venous thrombosis. <i>British Journal of Haematology</i> , 2012, 157, 753-761.	2.5	16
153	TFPI Alpha and Beta Regulate mRNAs and microRNAs Involved in Cancer Biology and in the Immune System in Breast Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e47184.	2.5	13
154	Kunnskapsbasert praksis for pasienter med alvorlig venøs trombose. <i>Tidsskrift for Den Norske Lægeforening</i> , 2012, 132, 1215-1216.	0.2	1
155	Protein C Mutation (A267T) Results in ER Retention and Unfolded Protein Response Activation. <i>PLoS ONE</i> , 2011, 6, e24009.	2.5	9
156	The association of inherited thrombophilia and intrauterine fetal death. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 651-656.	1.0	7
157	Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. <i>Blood Coagulation and Fibrinolysis</i> , 2011, 22, 254-259.	1.0	15
158	Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the rs6025 (factor V Leiden) polymorphism. <i>British Journal of Haematology</i> , 2011, 154, 241-247.	2.5	12
159	Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1261-1263.	3.8	16
160	Long-term quality of life after pregnancy-related deep vein thrombosis and the influence of socioeconomic factors and comorbidity. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1931-1936.	3.8	31
161	D-dimer levels and stroke progression in patients with acute ischemic stroke and atrial fibrillation. <i>Acta Neurologica Scandinavica</i> , 2011, 124, 40-44.	2.1	16
162	Incidence and risk factors of fetal death in Norway: a case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 390-397.	2.8	15

#	ARTICLE	IF	CITATIONS
163	Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. <i>BMC Cancer</i> , 2011, 11, 357.	2.6	40
164	Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias. <i>Leukemia and Lymphoma</i> , 2011, 52, 1157-1159.	1.3	0
165	Practical Viewpoints on the Diagnosis and Management of Heparin-Induced Thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 328-336.	2.7	22
166	An Exploratory Trial of Cyclooxygenase Type 2 Inhibitor in HIV-1 Infection: Downregulated Immune Activation and Improved T Cell-Dependent Vaccine Responses. <i>Journal of Virology</i> , 2011, 85, 6557-6566.	3.4	58
167	Improved Functional Outcome After Additional Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Results of a Randomized Controlled Clinical Trial (The CaVenT Study). <i>Blood</i> , 2011, 118, LBA-1-LBA-1.	1.4	4
168	Improved Functional Outcome After Additional Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Results of a Randomized Controlled Clinical Trial (The CaVenT Study). <i>Blood</i> , 2011, 118, LBA-1-LBA-1.	1.4	0
169	Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 516-521.	1.0	12
170	Visualization of deep veins and detection of deep vein thrombosis (DVT) with balanced turbo field echo (bâ€TFE) and contrastâ€enhanced T1 fast field echo (CEâ€FFE) using a blood pool agent (BPA). <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 416-424.	3.4	28
171	Overexpression of both TFPI ¹ and TFPI ² induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. <i>Molecular Carcinogenesis</i> , 2010, 49, 951-963.	2.7	25
172	Functional characterization of the protein C A267T mutation: evidence for impaired secretion due to defective intracellular transport. <i>BMC Cell Biology</i> , 2010, 11, 67.	3.0	12
173	Interaction between tissue factor pathway inhibitor and factor V levels on the risk of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1130-1132.	3.8	7
174	Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2443-2449.	3.8	34
175	Immunobiology of Heparin-Induced Thrombocytopenia. <i>Current Topics in Microbiology and Immunology</i> , 2010, 341, 193-202.	1.1	4
176	Functional characterization of polymorphisms in the human TFPI gene. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 106-111.	2.1	19
177	Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis. <i>Thrombosis Research</i> , 2010, 125, 230-234.	1.7	9
178	The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis â€ a population-based case-control study. <i>Thrombosis Research</i> , 2010, 125, e222-e227.	1.7	38
179	Thrombosis Research â€ Affiliation with the European Thrombosis Research Organization (ETRO). <i>Thrombosis Research</i> , 2010, 125, 1.	1.7	38
180	Prophylaxis against Prosthetic Mitral Valve Thrombosis with Unfractionated Heparin Administered by an Elastometric Infusion Pump. <i>Thrombosis Research</i> , 2010, 126, e232-e234.	1.7	3

#	ARTICLE	IF	CITATIONS
181	Candidate Gene Polymorphisms and the Risk for Pregnancy Related Venous Thrombosis. <i>Blood</i> , 2010, 116, 4203-4203.	1.4	0
182	Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2009, 50, 998-1004.	1.3	12
183	Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. <i>Leukemia</i> , 2009, 23, 162-169.	7.2	69
184	Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1268-1275.	3.8	245
185	Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific questionnaire. <i>Scandinavian Journal of Caring Sciences</i> , 2009, 23, 369-374.	2.1	21
186	Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability. <i>Thrombosis Research</i> , 2009, 123, 851-855.	1.7	3
187	Management of pregnant women with mechanical heart valve prosthesis: Thromboprophylaxis with Low molecular weight heparin. <i>Thrombosis Research</i> , 2009, 124, 262-267.	1.7	108
188	Birger Blombäck 1926-2008 - A Memorial. <i>Thrombosis Research</i> , 2009, 123, 803-804.	1.7	0
189	Thrombosis Research - Introduction of e-pages. <i>Thrombosis Research</i> , 2009, 124, 251.	1.7	1
190	Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). <i>Thrombosis Research</i> , 2009, 124, 515.	1.7	2
191	Mechanisms of thrombosis related to hormone therapy. <i>Thrombosis Research</i> , 2009, 123, S70-S73.	1.7	46
192	Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium - a register-based case-control study. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 233.e1-233.e7.	1.3	328
193	Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2008, 115, 773-779.	2.3	21
194	The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 393-395.	3.8	36
195	Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 905-912.	3.8	329
196	Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 928-934.	3.8	23
197	Increased acquired activated protein C resistance in unselected patients with hematological malignancies. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1482-1487.	3.8	29
198	Hypercoagulability in patients with haematological neoplasia: No apparent initiation by tissue factor. <i>Thrombosis and Haemostasis</i> , 2008, 99, 1040-1048.	3.4	43

#	ARTICLE	IF	CITATIONS
199	Adjunctive Catheter-Directed Venous Thrombolysis in Iliofemoral Deep Vein Thrombosis; Short-Term Results from the CaVenT Study, a Multicenter Randomized Controlled Trial. <i>Blood</i> , 2008, 112, 989-989.	1.4	3
200	Increased Bone Marrow Microvascular Density in Hematologic Malignancies. <i>Blood</i> , 2008, 112, 5456-5456.	1.4	0
201	The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 393-395.	3.8	16
202	Multidetector computed tomography (MDCT) in the diagnosis of pulmonary embolism: interobserver agreement among radiologists with varied levels of experience. <i>Acta Radiologica</i> , 2007, 48, 165-170.	1.1	60
203	The Factor V Leiden, Prothrombin Gene 20210GA, Methylenetetrahydrofolate Reductase 677CT and Platelet Glycoprotein IIIa 1565TC Mutations in Patients With Acute Ischemic Stroke and Atrial Fibrillation. <i>Stroke</i> , 2007, 38, 1069-1071.	2.0	37
204	Hormone therapy and raloxifene reduce the coagulation inhibitor potential. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 455-460.	1.0	2
205	Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia. <i>Thrombosis Research</i> , 2007, 120, 21-27.	1.7	16
206	D-dimer level is associated with the extent of pulmonary embolism. <i>Thrombosis Research</i> , 2007, 120, 281-288.	1.7	93
207	Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. <i>Thrombosis Research</i> , 2007, 120, 371-379.	1.7	29
208	Validation of a new D-dimer microparticle enzyme immunoassay (AxSYM D-Dimer) in patients with suspected pulmonary embolism (PE). <i>Thrombosis Research</i> , 2007, 120, 471-476.	1.7	17
209	Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis-the CaVenT Study: Rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). <i>American Heart Journal</i> , 2007, 154, 808-814.	2.7	97
210	Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated peripheral blood mononuclear cells. <i>Thrombosis and Haemostasis</i> , 2007, 97, 822-829.	3.4	105
211	The association between the proximal extension of the clot and the severity of pulmonary embolism (PE): a proposal for a new radiological score for PE. <i>Journal of Internal Medicine</i> , 2007, 261, 74-81.	6.0	64
212	Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. <i>British Journal of Haematology</i> , 2007, 136, 131-137.	2.5	44
213	Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2204-2210.	3.8	54
214	Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. <i>Maturitas</i> , 2006, 55, 278-287.	2.4	28
215	Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured. <i>Thrombosis Research</i> , 2006, 118, 281-287.	1.7	2
216	A daily glass of red wine induces a prolonged reduction in plasma viscosity: a randomized controlled trial. <i>Blood Coagulation and Fibrinolysis</i> , 2006, 17, 471-476.	1.0	17

#	ARTICLE	IF	CITATIONS
217	Hormone replacement therapy and risk of venous thromboembolism - still unresolved questions. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 68-69.	3.8	1
218	Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation?. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 1840-1842.	3.8	14
219	The performance of STA-Liatest D-dimer assay in out-patients with suspected pulmonary embolism. <i>British Journal of Haematology</i> , 2006, 132, 210-215.	2.5	24
220	Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. <i>British Journal of Haematology</i> , 2006, 132, 333-338.	2.5	14
221	Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1. <i>BMC Cardiovascular Disorders</i> , 2006, 6, 40.	1.7	22
222	Are There Patients With Acute Ischemic Stroke and Atrial Fibrillation That Benefit From Low Molecular Weight Heparin?. <i>Stroke</i> , 2006, 37, 452-455.	2.0	26
223	Decreased Lung Cancer Survival With Hormone-Replacement Therapy: Caused by a Decreased Tissue Factor Pathway Inhibitor Level?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2683-2684.	1.6	2
224	Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. <i>European Heart Journal</i> , 2006, 27, 1038-1047.	2.2	688
225	A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 651-658.	3.8	39
226	Determinants of the APTT- and ETP-based APC sensitivity tests. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1488-1494.	3.8	87
227	Management of suspected pulmonary embolism (PE) by D-dimer and multi-slice computed tomography in outpatients: an outcome study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1926-1932.	3.8	81
228	The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. <i>Maturitas</i> , 2005, 52, 111-118.	2.4	55
229	Angiogenesis and Hemostasis in Hematological Neoplasias. <i>Current Drug Targets</i> , 2005, 6, 683-699.	2.1	8
230	Production of Tissue Factor Pathway Inhibitor in Endothelial Cell Cultures Is Reduced by Estrogens, Selective Estrogen Receptor Modifiers, and a Selective Estrogen Receptor Downregulator.. <i>Blood</i> , 2005, 106, 3961-3961.	1.4	1
231	Coagulation activation in young survivors of myocardial infarction (MI) - a population-based case-control study. <i>Thrombosis and Haemostasis</i> , 2004, 92, 178-184.	3.4	19
232	Tissue factor pathway inhibitor revisited. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2242-2243.	3.8	0
233	The viscosity of fibrinogen subfractions and of EDTA denatured fibrinogen do not differ from that of native fibrinogen. <i>Thrombosis Research</i> , 2004, 113, 51-56.	1.7	4
234	Deep vein thrombosis after elective cesarean section. <i>Thrombosis Research</i> , 2004, 113, 283-288.	1.7	58

#	ARTICLE	IF	CITATIONS
235	The ability of three global plasma assays to recognize thrombophilia. <i>Thrombosis Research</i> , 2004, 113, 411-417.	1.7	17
236	INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1223-1231.	3.4	41
237	Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2003, 82, 679-680.	2.8	58
238	Smoking and relation to other risk factors in postmenopausal women with coronary artery disease, with particular reference to whole blood viscosity and beta-cell function. <i>Journal of Internal Medicine</i> , 2003, 253, 232-239.	6.0	12
239	Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2003, 110, 139-144.	2.3	60
240	Acute hypoxia and activation of coagulation. <i>Lancet, The</i> , 2003, 362, 997-998.	13.7	10
241	Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. <i>Blood</i> , 2003, 101, 4387-4392.	1.4	222
242	Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2003, 82, 679-680.	2.8	1
243	Hormone Replacement Therapy Does Not Affect Plasma Homocysteine in Postmenopausal Women with Coronary Artery Disease. <i>Cardiology</i> , 2002, 98, 6-12.	1.4	12
244	Perioperative management of oral anticoagulant therapy. <i>Thrombosis Research</i> , 2002, 108, 1-2.	1.7	10
245	Air travel and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2002, 108, 15-17.	1.7	7
246	TFPI fractions in plasma from patients with systemic meningococcal disease. <i>Thrombosis Research</i> , 2002, 108, 347-353.	1.7	7
247	Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. <i>British Journal of Haematology</i> , 2002, 119, 1011-1016.	2.5	37
248	Heparin and aspirin in stroke. <i>Lancet, The</i> , 2001, 357, 1044-1045.	13.7	1
249	Hypobaric hypoxia. <i>Lancet, The</i> , 2001, 357, 955-956.	13.7	4
250	Hemostatic Activation in Acute Ischemic Stroke. <i>Thrombosis Research</i> , 2001, 101, 13-21.	1.7	48
251	Serum Lipids and Regulation of Tissue Factor-Induced Coagulation in Middle-Aged Men. <i>Thrombosis Research</i> , 2001, 102, 3-13.	1.7	16
252	Deep-vein thrombosis in long-haul flights. <i>Lancet, The</i> , 2001, 358, 837-838.	13.7	5

#	ARTICLE	IF	CITATIONS
253	The Effects of Hormone Replacement Therapy (HRT) on Hemostatic Variables in Women with Previous Venous Thromboembolism – Results from a Randomized, Double-Blind, Clinical Trial. <i>Thrombosis and Haemostasis</i> , 2001, 85, 775-781.	3.4	102
254	Validity and Reliability of Simple Questions in Assessing Short- and Long-Term Outcome in Norwegian Stroke Patients. <i>Cerebrovascular Diseases</i> , 2001, 11, 305-310.	1.7	6
255	Low molecular weight heparin prevents activation of coagulation in a hypobaric environment. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 371-374.	1.0	26
256	Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a ‘procoagulant state’: effects of bezafibrate therapy. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 705-712.	1.0	5
257	Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. <i>British Journal of Haematology</i> , 2001, 115, 415-420.	2.5	80
258	The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism—results from a randomized, double-blind, clinical trial. <i>Thrombosis and Haemostasis</i> , 2001, 85, 775-81.	3.4	14
259	Cerebral Microembolus Detection in an Unselected Acute Ischemic Stroke Population. <i>Cerebrovascular Diseases</i> , 2000, 10, 403-408.	1.7	23
260	Effect of ω -3 Fatty Acids and Simvastatin on Hemostatic Risk Factors and Postprandial Hyperlipemia in Patients With Combined Hyperlipemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 259-265.	2.4	92
261	Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 343-348.	1.0	19
262	Physiological Function of Tissue Factor Pathway Inhibitor and Interaction with Heparins. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 48-56.	0.3	22
263	Heparin versus aspirin in ischaemic stroke. <i>Lancet, The</i> , 2000, 356, 505.	13.7	1
264	Reduction of Factor FVIIa Activity During Heparin Therapy. <i>Thrombosis Research</i> , 2000, 100, 389-396.	1.7	3
265	Discrepancy between Fibrinogen Concentrations Determined by Clotting Rate and Clottability Assays during the Acute-Phase Reaction. <i>Thrombosis Research</i> , 2000, 100, 397-403.	1.7	21
266	Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. <i>Thrombosis Research</i> , 2000, 100, 413-417.	1.7	18
267	A New Sensitive Chromogenic Substrate Assay of Tissue Factor Pathway Inhibitor Type 1. <i>Thrombosis Research</i> , 2000, 97, 463-472.	1.7	30
268	The Effects of Hormone Replacement Therapy on Hemostatic Variables in Women with Angiographically Verified Coronary Artery Disease. <i>Thrombosis Research</i> , 2000, 98, 19-27.	1.7	44
269	Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. <i>Lancet, The</i> , 2000, 355, 1205-1210.	13.7	408
270	Association between acute hypobaric hypoxia and activation of coagulation in human beings. <i>Lancet, The</i> , 2000, 356, 1657-1658.	13.7	233

#	ARTICLE	IF	CITATIONS
271	Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). <i>Thrombosis and Haemostasis</i> , 2000, 84, 961-7.	3.4	70
272	Oral Contraceptives Highlight the Genotype-Specific Association Between Serum Phospholipids and Activated Factor VII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2024-2028.	2.4	7
273	Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1999, 78, 191-197.	2.8	22
274	Toxicity of gamma irradiated liposomes.. <i>International Journal of Pharmaceutics</i> , 1999, 178, 33-46.	5.2	15
275	Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. <i>British Journal of Haematology</i> , 1999, 105, 641-647.	2.5	20
276	Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. <i>British Journal of Haematology</i> , 1999, 107, 756-762.	2.5	38
277	Do Antiphospholipid Antibodies Interfere with Tissue Factor Pathway Inhibitor?. <i>Thrombosis Research</i> , 1999, 94, 213-220.	1.7	16
278	Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. <i>British Journal of Haematology</i> , 1998, 101, 638-646.	2.5	54
279	Differential Effects of Low Molecular Weight Heparin and Unfractionated Heparin on Circulating Levels of Antithrombin and Tissue Factor Pathway Inhibitor (TFPI). <i>Thrombosis Research</i> , 1998, 91, 177-181.	1.7	44
280	REDUCED C4b-BINDING PROTEIN IN PREECLAMPSIA. <i>Thrombosis Research</i> , 1997, 85, 153-158.	1.7	8
281	AN ENZYME LINKED IMMUNOSORPTION ASSAY FOR TISSUE FACTOR PATHWAY INHIBITOR. <i>Thrombosis Research</i> , 1997, 87, 447-459.	1.7	31
282	Contribution of Factor VII Genotype to Activated FVII Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2548-2553.	2.4	94
283	Tissue Factor Pathway Inhibitor: Clinical Deficiency States. <i>Thrombosis and Haemostasis</i> , 1997, 78, 467-470.	3.4	35
284	Tissue factor pathway inhibitor: clinical deficiency states. <i>Thrombosis and Haemostasis</i> , 1997, 78, 467-70.	3.4	3
285	BINDING OF TISSUE FACTOR PATHWAY INHIBITOR TO CULTURED ENDOTHELIAL CELLS-INFLUENCE OF GLYCOSAMINOGLYCANS. <i>Thrombosis Research</i> , 1996, 84, 267-278.	1.7	31
286	Tissue Factor Pathway Inhibitor (Tfpi) â€“ An Update. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1996, 26, 154-165.	0.3	32
287	Depletion of Intravascular Pools of Tissue Factor Pathway Inhibitor (TFPI) during Repeated or Continuous Intravenous Infusion of Heparin in Man. <i>Thrombosis and Haemostasis</i> , 1996, 76, 703-709.	3.4	57
288	Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?. <i>Journal of Internal Medicine</i> , 1995, 237, 323-329.	6.0	13

#	ARTICLE	IF	CITATIONS
289	Activated protein C resistance and graft occlusion after coronary artery bypass surgery. <i>Thrombosis Research</i> , 1995, 79, 223-226.	1.7	23
290	Effect of Cholesterol Lowering on Intravascular Pools of TFPI and Its Anticoagulant Potential in Type II Hyperlipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995, 15, 879-885.	2.4	49
291	Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1994, 14, 223-229.	3.9	97
292	Heparin Treatment in 52 Patients with Progressive Ischemic Stroke. <i>Cerebrovascular Diseases</i> , 1994, 4, 101-105.	1.7	15
293	Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. <i>Blood Coagulation and Fibrinolysis</i> , 1994, 5, 755-760.	1.0	21
294	Deep vein thrombosis: a 7-year follow-up study. <i>Journal of Internal Medicine</i> , 1993, 234, 71-75.	6.0	57
295	Heparin Treatment of Recent Transient Ischemic Attacks: A Safety Study. <i>Cerebrovascular Diseases</i> , 1993, 3, 174-176.	1.7	2
296	The present status of tissue factor pathway inhibitor. <i>Blood Coagulation and Fibrinolysis</i> , 1992, 3, 439-449.	1.0	97
297	Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. <i>Cancer</i> , 1992, 70, 2067-2072.	4.1	23
298	Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. <i>Thrombosis Research</i> , 1991, 62, 607-614.	1.7	28
299	Extrinsic Pathway Inhibitor – The Key to Feedback Control of Blood Coagulation Initiated by Tissue Thromboplastin. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1991, 21, 219-239.	0.3	19
300	Heparin Requires both Antithrombin and Extrinsic Pathway Inhibitor for Its Anticoagulant Effect in Human Blood. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1991, 21, 254-257.	0.3	16
301	Detection of arterial emboli using Doppler ultrasound in rabbits.. <i>Stroke</i> , 1991, 22, 253-258.	2.0	231
302	Chromogenic substrate assay of extrinsic pathway inhibitor (EPI). <i>Blood Coagulation and Fibrinolysis</i> , 1991, 2, 425-434.	1.0	82
303	Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1991, 11, 138-145.	3.9	83
304	Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991, 88, 708-712.	7.1	176
305	Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. <i>Blood Coagulation and Fibrinolysis</i> , 1991, 2, 713-722.	1.0	72
306	Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. <i>Blood Coagulation and Fibrinolysis</i> , 1991, 2, 425-33.	1.0	14

#	ARTICLE	IF	CITATIONS
307	Indices of Hypercoagulation in Cancer as Compared with Those in Acute Inflammation and Acute Infarction. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1990, 20, 253-262.	0.3	10
308	A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Seminars in Thrombosis and Hemostasis, 1990, 16 Suppl, 25-33.	2.7	15
309	Extrinsic Pathway Inhibitor in Postoperative/Posttraumatic Septicemia: Increased Levels in Fatal Cases. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1989, 19, 189-195.	0.3	18
310	Factor VII and extrinsic pathway inhibitor in acute coronary disease. British Journal of Haematology, 1989, 72, 391-396.	2.5	58
311	Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. Journal of Internal Medicine, 1989, 225, 311-316.	6.0	31
312	The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide a in systemic meningococcal disease. Thrombosis Research, 1989, 55, 459-470.	1.7	177
313	Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. Thrombosis Research, 1989, 55, 665-670.	1.7	29
314	Extrinsic Coagulation Pathway Inhibitor during Recombinant Factor VIIa Infusion. Thrombosis and Haemostasis, 1989, 62, 1146-1146.	3.4	2
315	Extrinsic Pathway Inhibitor in Elective Surgery: A Comparison with other Coagulation Inhibitors. Thrombosis and Haemostasis, 1989, 62, 856-860.	3.4	30
316	Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. Thrombosis and Haemostasis, 1989, 62, 856-60.	3.4	4
317	High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. Acta Chirurgica Scandinavica, 1989, 155, 389-93.	0.2	23
318	Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI). Thrombosis Research, 1988, 50, 803-813.	1.7	401
319	A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thrombosis Research, 1987, 47, 389-400.	1.7	111
320	PREACTIVATION AND INHIBITION OF EXTRINSIC COAGULATION PATHWAY IN ACUTE CORONARY DISEASE. Thrombosis and Haemostasis, 1987, 58, 0225.	3.4	0
321	â€œNEWâ€-COAGULATION INHIBITORS LEVELS IN PNEUMONIA DISSEMINATED INTRAVASCULAR COAGULATION AND LIVER DISEASES. , 1987, 58, 1115.		0
322	EXTRINSIC PATHWAY INHIBITOR (EPI):A SENSITIVE CHROMOGENIC SUBSTRATE ASSAY DEMONSTRATES THE RELEASE OF EPI TO THE BLOOD AFTER INJECTION OF HEPARIN. Thrombosis and Haemostasis, 1987, 58, 1116.	3.4	1
323	EXTRINSIC PATHWAY INHIBITOR (EPI) DURING ELECTUVE SUGERY : A COMPARISON WITH OTHER COAGULATION INHIBITORS. , 1987, 58, 1526.		9